Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA-mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study-MedSci.cn

Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA-mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study

Ales-Martinez, JE; Morales, S; Abad, MF; Sanchez-Rovira, P; Bofill, FJS; Lahuerta, A; Garcia-Saenz, JA; Llinas, IG; Redondo, TD; Ferrer, N; Caranana, V; Lopez, R; Soler, SEA; Bermejo, B; de la Haba, J; Zamora, P; Balmana, J; Lopez-Miranda, E; Cortes,

ANNALS OF ONCOLOGY, 2019; 30 (): 139